The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
2 other identifiers
interventional
469
12 countries
76
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 diabetes-mellitus-type-2
Started May 2010
Typical duration for phase_3 diabetes-mellitus-type-2
76 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 1, 2010
CompletedFirst Posted
Study publicly available on registry
April 20, 2010
CompletedStudy Start
First participant enrolled
May 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2012
CompletedResults Posted
Study results publicly available
May 29, 2013
CompletedJune 20, 2013
June 1, 2013
1.3 years
April 1, 2010
April 10, 2013
June 12, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in HbA1c From Baseline to Week 26
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Day 1 (Baseline) and Week 26
Secondary Outcomes (6)
Percentage of Patients With HbA1c <7% at Week 26
Week 26
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
Day 1 (Baseline) and Week 26
Percent Change in Body Weight From Baseline to Week 26
Day 1 (Baseline) and Week 26
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26
Day 1 (Baseline) and Week 26
Percent Change in Triglycerides From Baseline to Week 26
Day 1 (Baseline) and Week 26
- +1 more secondary outcomes
Study Arms (3)
Canagliflozin 100 mg
EXPERIMENTALEach patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Canagliflozin 300 mg
EXPERIMENTALEach patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Placebo
PLACEBO COMPARATOREach patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Interventions
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
The patient's stable dose of background metformin therapy should be continued throughout the study.
The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Eligibility Criteria
You may qualify if:
- All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea
- Patients in the study must have a HbA1c between \>=7 and \<=10.5%
- Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)
You may not qualify if:
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (76)
Unknown Facility
Huntsville, Alabama, United States
Unknown Facility
Little Rock, Alaska, United States
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Chino, California, United States
Unknown Facility
Fair Oaks, California, United States
Unknown Facility
Roseville, California, United States
Unknown Facility
Wes Hills, California, United States
Unknown Facility
Waterbury, Connecticut, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
New Port Richey, Florida, United States
Unknown Facility
Ocala, Florida, United States
Unknown Facility
St. Petersburg, Florida, United States
Unknown Facility
West Palm Beach, Florida, United States
Unknown Facility
Augusta, Georgia, United States
Unknown Facility
Roswell, Georgia, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Lexington, Kentucky, United States
Unknown Facility
New Orleans, Louisiana, United States
Unknown Facility
Reisterstown, Maryland, United States
Unknown Facility
Olive Branch, Mississippi, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
Westfield, New York, United States
Unknown Facility
Greenville, North Carolina, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Tulsa, Oklahoma, United States
Unknown Facility
Medford, Oregon, United States
Unknown Facility
Altoona, Pennsylvania, United States
Unknown Facility
Harleysville, Pennsylvania, United States
Unknown Facility
Levittown, Pennsylvania, United States
Unknown Facility
Sellersville, Pennsylvania, United States
Unknown Facility
Greer, South Carolina, United States
Unknown Facility
Bryan, Texas, United States
Unknown Facility
Dallas, Texas, United States
Unknown Facility
DeSoto, Texas, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
South Burlington, Vermont, United States
Unknown Facility
Wenatchee, Washington, United States
Unknown Facility
Freemantle, Australia
Unknown Facility
Heidelberg Heights, Australia
Unknown Facility
Meadowbrook, Australia
Unknown Facility
Nedlands, Australia
Unknown Facility
Wollongong, Australia
Unknown Facility
Aalst, Belgium
Unknown Facility
Bonheiden, Belgium
Unknown Facility
Edegem, Belgium
Unknown Facility
Leuven, Belgium
Unknown Facility
Corbeil-Essonnes, France
Unknown Facility
La Rochelle, France
Unknown Facility
Le Creusot, France
Unknown Facility
Poitiers, France
Unknown Facility
Vénissieux, France
Unknown Facility
Guatemala City, Guatemala
Unknown Facility
Balatonfüred, Hungary
Unknown Facility
Budapest, Hungary
Unknown Facility
Győr, Hungary
Unknown Facility
Zalaegerszeg, Hungary
Unknown Facility
Haifa, Israel
Unknown Facility
Holon, Israel
Unknown Facility
Jerusalem, Israel
Unknown Facility
Tel Aviv, Israel
Unknown Facility
Guadalajara, Mexico
Unknown Facility
Monterrey, Mexico
Unknown Facility
Carolina, Puerto Rico
Unknown Facility
Trujillo Alto, Puerto Rico
Unknown Facility
Arkhangelsk, Russia
Unknown Facility
Saint Petersburg, Russia
Unknown Facility
Samara, Russia
Unknown Facility
Alicante, Spain
Unknown Facility
Almería, Spain
Unknown Facility
Málaga, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Belfast, United Kingdom
Unknown Facility
Bolton, United Kingdom
Unknown Facility
Liverpool, United Kingdom
Unknown Facility
Manchester, United Kingdom
Related Publications (17)
Cai J, Delahanty LM, Akapame S, Slee A, Traina S. Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. Patient. 2018 Jun;11(3):341-352. doi: 10.1007/s40271-017-0290-4.
PMID: 29313267DERIVEDDavies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7.
PMID: 28327140DERIVEDPfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0.
PMID: 28241822DERIVEDGilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther. 2017 Apr;8(2):451-458. doi: 10.1007/s13300-017-0232-0. Epub 2017 Feb 14.
PMID: 28197834DERIVEDQiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4.
PMID: 27977934DERIVEDJohn M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868.
PMID: 27600862DERIVEDWatts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
PMID: 26580237DERIVEDLavalle-Gonzalez FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14.
PMID: 26579834DERIVEDBlonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28.
PMID: 26373629DERIVEDGavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693-702. doi: 10.1185/03007995.2015.1067192. Epub 2015 Sep 4.
PMID: 26121561DERIVEDCefalu WT, Stenlof K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27.
PMID: 25813214DERIVEDWeir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82. doi: 10.1111/jch.12425. Epub 2014 Oct 20.
PMID: 25329038DERIVEDUsiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014 May;126(3):16-34. doi: 10.3810/pgm.2014.05.2753.
PMID: 24918789DERIVEDWeir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
PMID: 24786834DERIVEDSinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A, Shaw W, Usiskin K, Desai M, Meininger G. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014 Apr 18;14:37. doi: 10.1186/1472-6823-14-37.
PMID: 24742013DERIVEDPolidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014 May;57(5):891-901. doi: 10.1007/s00125-014-3196-x. Epub 2014 Mar 1.
PMID: 24585202DERIVEDNyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
PMID: 24517339DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Vice President, Franchise Medical Leader, Cardiovascular & Metabolism Franchise
- Organization
- Janssen Research & Development, LLC
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC C. Clinical Trial
Janssen Research & Development, LLC
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 1, 2010
First Posted
April 20, 2010
Study Start
May 1, 2010
Primary Completion
September 1, 2011
Study Completion
April 1, 2012
Last Updated
June 20, 2013
Results First Posted
May 29, 2013
Record last verified: 2013-06